INSUBCONTINENT EXCLUSIVE:
NEW DELHI: Stock of Dr Reddy's Laboratories on Wednesday appeared unmoved by reports of AstraZeneca filing a lawsuit against the domestic
drug maker in the Delhi High Court.
The legal move is a bid to stop DRL from launching generic versions of Brilinta, AstraZeneca's
blockbuster medicine for heart ailments.
The UK biopharmaceutical company claims that the potential launch of the copies infringes one of
its existing patents on the drug, ET reported.
At 10 am, Dr Reddy's Laboratories rose 0.22 per cent to Rs 2,080.45
AstraZeneca's Indian arm fell a similar percentage to Rs 1,462.55.
The Delhi High Court asked DRL on Tuesday to file a reply to the
lawsuit and will hear its arguments on July 31, said lawyers aware of the developments
Until then, DRL cannot launch the generic version of the drug, they told ET.
Copies of the drug can be manufactured only after all the
The case is making news as DRL has not been seen as an aggressive challenger of drug patents in India.
Brilinta, which is used for reducing
chances of heart attacks or strokes by preventing blood clots in vessels, achieved blockbuster status in 2017 when it raked in over $1
